Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Bank of America

Keros Therapeutics (NASDAQ:KROS - Get Free Report) was downgraded by equities research analysts at Bank of America from a "buy" rating to a "neutral" rating in a research note issued on Tuesday, MarketBeat reports. They presently have a $18.00 price objective on the stock, down from their prior price objective of $32.00. Bank of America's target price would suggest a potential upside of 30.91% from the company's previous close.

Other equities research analysts have also issued research reports about the stock. Wedbush reiterated a "neutral" rating and set a $15.00 price objective on shares of Keros Therapeutics in a report on Friday, May 30th. Truist Financial reduced their price objective on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Wells Fargo & Company lowered their target price on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, February 27th. HC Wainwright cut their price target on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, Scotiabank lowered their price objective on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research note on Monday, May 12th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Keros Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $30.56.

Keros Therapeutics Stock Down 2.4%

NASDAQ:KROS traded down $0.34 during mid-day trading on Tuesday, hitting $13.75. 1,346,767 shares of the stock traded hands, compared to its average volume of 861,491. Keros Therapeutics has a 52 week low of $9.12 and a 52 week high of $72.37. The stock has a market capitalization of $558.46 million, a price-to-earnings ratio of -2.64 and a beta of 1.31. The firm's 50 day moving average is $13.52 and its two-hundred day moving average is $17.46.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $211.25 million during the quarter, compared to analyst estimates of $84.62 million. During the same period last year, the company earned ($1.21) EPS. As a group, research analysts predict that Keros Therapeutics will post -4.74 EPS for the current year.

Insider Buying and Selling at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the stock in a transaction on Wednesday, April 9th. The stock was acquired at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the acquisition, the insider now owns 4,392,737 shares in the company, valued at $44,498,425.81. The trade was a 27.01% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 20.60% of the stock is owned by insiders.

Institutional Trading of Keros Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its stake in shares of Keros Therapeutics by 7,690.3% during the first quarter. GAMMA Investing LLC now owns 2,415 shares of the company's stock worth $237,000 after buying an additional 2,384 shares during the period. FNY Investment Advisers LLC purchased a new position in Keros Therapeutics in the 1st quarter worth $25,000. CWM LLC lifted its position in Keros Therapeutics by 10,157.7% during the 1st quarter. CWM LLC now owns 2,667 shares of the company's stock worth $27,000 after acquiring an additional 2,641 shares during the period. AlphaQuest LLC grew its stake in Keros Therapeutics by 469.0% during the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock valued at $57,000 after purchasing an additional 2,964 shares during the last quarter. Finally, Virtus ETF Advisers LLC increased its holdings in shares of Keros Therapeutics by 107.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock valued at $61,000 after purchasing an additional 1,998 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.